Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

What Is Imfinzi, and Why Does It Matter? Imfinzi (durvalumab) is a prescription immunotherapy medicine used to treat different types of cancer. The FDA has approved the combination of Imfinzi and ...

Using zebrafish "avatars," an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López—a former Ph.D.

Using zebrafish "Avatars", an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Based on POTOMAC Phase III trial results ...

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of Urologic Oncology Annual Meeting in Dallas, Dec. 4–6. The study ...

Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a ...

Emerging solutions are bringing us closer than ever to tackling these unmet medical needs, enhancing patient outcomes and improving overall quality of life for those with NMIBC. Cretostimogene ...

There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of cretostimogene ...

TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...

For people with non–muscle invasive bladder cancer (NMIBC), the reality can be especially pronounced. The disease is often persistent, requiring repeated treatments, frequent monitoring, and ongoing ...